Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Boehringer Ingelheim
McKinsey
Daiichi Sankyo
Farmers Insurance
Julphar
Cipla
Express Scripts
US Army
McKesson

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,458,818

« Back to Dashboard

Which drugs does patent 6,458,818 protect, and when does it expire?

Patent 6,458,818 protects KALETRA and is included in one NDA.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 6,458,818
Title: Pharmaceutical composition
Abstract:A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).
Inventor(s): Lipari; John (Racine, WI), Al-Razzak; Laman A. (Lake Forest, IL), Ghosh; Soumojeet (Lindenhurst, IL), Gao; Rong (Park City, IL), Kaul; Dilip (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/347,077
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,458,818

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,458,818

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,232,333 Pharmaceutical composition ➤ Try a Free Trial
6,521,651 Pharmaceutical composition ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Chinese Patent Office
US Army
Accenture
Boehringer Ingelheim
Harvard Business School
Farmers Insurance
Medtronic
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot